BRAF V600E突变与甲状腺乳头状癌的研究进展

Progress of BRAF V600E mutation and papillary thyroid carcinoma

甲状腺乳头状癌(PTC)起源于甲状腺滤泡上皮细胞,预后一般较好。但近年来PTC的发病率急剧上升,严重影响公众健康,甲状腺乳头状癌常被分为几种亚型:经典型、滤泡亚型、高细胞亚型、平头钉亚型及弥漫硬化型等,不同亚型的侵袭性有所不同。BRAF V600E突变是甲状腺乳头状癌的最常见的分子标志物,也是近年来的分子研究热点,和PTC的发生发展机制、侵袭性及预后密切相关。随着BRAF V600E突变研究的不断深入,关于它与PTC之间关系的矛盾点及争论点慢慢浮现,本文就近5年来的相关文献进行综述,主要从BRAF V600E突变与PTC的作用发生机制、临床病理特征关系、预后、指导临床治疗及相关基因联合等方面进行阐述,并针对当前的争议点及矛盾点进行比较分析。

Papillary thyroid carcinoma originated in thyroid follicular epithelial cells,the prognosis is generally better.However,the incidence of PTC has risen sharply in recent years,seriously affecting public health.Papillary thyroid carcinoma is often divided into several subtypes:Classical,Follicular-variant,Tall cell subtype,Hobnail variant and Diffuse sclerosis,et al.The aggressiveness of different subtypes is different.BRAF V600E mutation is the most common molecular marker of papillary thyroid carcinoma and is also a hot spot in molecular research in recent years.It is closely related to the occurrence,development mechanism,invasion and prognosis of PTC.With the deepening of BRAF V600E mutation research and its contradictory points and controversies about the relationship between PTC and BRAF V600E,this review summarizes the relevant literature in the recent five years mainly from the mechanisms of BRAF V600E m utation and PTC,the clinicopathological features relationship,prognosis,guiding clinical treatment and related gene combination and so on.The dissertation analyzes the controversial and contradictory points in current literatures.